SAB Biotherapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 181.2K | $693.94K | 0.00% | New | 2026-03-31 |
| StateStreet | passive | 74.2K | $284.31K | 0.00% | Added+465.7% | 2026-03-31 |